Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
about
Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesPatient safety and minimizing risk with insulin administration - role of insulin degludecHypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.Comparison of intra-individual coefficients of variation on the paired sampling data when inter-individual variations are different between measures.Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.A review of the pharmacological properties of insulin degludec and their clinical relevance.Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patientsA Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trialSevere hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resourcesElderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).Basal insulin analogues in the management of diabetes mellitus: What progress have we made?A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions.Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India.Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials.Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience.Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study.Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes.The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analySafety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes.Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin.Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials.
P2860
Q26778763-501BE42F-5E45-417B-8F77-5E2FD846371EQ26784381-AEADF787-6CAB-4E62-9944-05C7478F115BQ27025548-39524287-D668-4080-A861-19B67F56257AQ31046934-6071AB7E-4FD7-4E27-B51B-B3029767CFA9Q31047906-CA07DCEB-35AD-40DD-B27D-3FC58F0BD0C8Q31154873-B361A29A-FFBC-4DE6-B8F9-99FD93D84AD5Q34436383-26A294BB-D6BF-4E66-A633-15F8DA357CE5Q34726423-9A79333F-7EC2-4997-A088-5BDB775F9B7FQ36637960-BBEFEB6A-ADD8-4926-A54F-572F84107C42Q36924024-335F8E75-2306-437F-A739-B824BC895908Q37227389-B286993C-87AC-4818-A0E5-505BA04197BAQ37279137-98BEFAEC-10C5-444E-BAB5-3DFE1C924656Q37321746-7ACC6A96-D009-4CA3-AFD5-D06673792EC4Q37343847-936D50F0-D286-4556-A0DD-CB1F1725364EQ37357320-D2694CB3-AEC7-4B43-99B1-AE728AEF551AQ38136581-DCC53BDB-29B3-4AC8-AEAB-8172823085F5Q38153337-EB17E9E0-7C57-4B03-B643-9405D33C0B81Q38199712-07B241D5-157F-4F19-B3B6-D7BEEB0B5737Q38393753-8B12C3AA-8616-4B4D-8D69-1AB11099F2F5Q38403664-9A7638E7-EC62-4D45-A8BC-E65331F8ABA7Q38470334-43B7D8B9-56C3-412A-A831-DD134ECFA99FQ38628035-5AC2402C-F5FD-45C8-8BCA-B6828252DAC7Q41200024-0829A851-4535-4F0A-8D3F-D610AB8C4912Q41906566-43C5EE0F-C24C-4714-9171-3CE9D9997664Q42382362-D696CB85-009C-4A46-8311-F80967F49474Q47149556-10E26750-5EAA-49F1-9753-210BE0901909Q47557627-A228FA53-4789-4393-A750-3A155074D5BCQ48262568-33633E69-AC03-4B69-9F7C-4306720864E7Q49365317-B9046EF2-BEB3-4704-A389-3061D4029687Q49928678-CAD34182-AE70-47F2-8238-73D9343EF42EQ50233425-BAE3FB1D-62D2-4596-B747-42BA12B15B64Q51130872-E1999B3B-19D7-4842-B6A3-B4C91562F04CQ53448284-D7ED60D5-E3D0-4D4B-B447-305EF3205F8FQ54857875-42CCAA10-4CBB-4352-BDAB-F040C97649F9Q55262674-1B790A72-8B07-4B06-AAE4-56A0982DBF8E
P2860
Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Insulin degludec compared with ...... -Asian, treat-to-target trial.
@ast
Insulin degludec compared with ...... -Asian, treat-to-target trial.
@en
type
label
Insulin degludec compared with ...... -Asian, treat-to-target trial.
@ast
Insulin degludec compared with ...... -Asian, treat-to-target trial.
@en
prefLabel
Insulin degludec compared with ...... -Asian, treat-to-target trial.
@ast
Insulin degludec compared with ...... -Asian, treat-to-target trial.
@en
P2093
P2860
P356
P1476
Insulin degludec compared with ...... -Asian, treat-to-target trial.
@en
P2093
Per Clauson
Soon Jib Yoo
Sungwoo Park
Søren C Tamer
Yasuhiko Iwamoto
Yukiko Onishi
P2860
P304
P356
10.1111/JDI.12102
P577
2013-06-03T00:00:00Z